Expertise

Ed Corbett

Senior Principal, Head of EMEA, EVERSANA™ CONSULTING

Expertise:

Consulting (Strategy Management & Regulatory), Digital Health, Digital Medicine, Digital Technology, Stakeholder Engagement & Promotion (Patients, Payers, Providers)

As the lead for EVERSANA’s EMEA management consulting practice, Ed specializes in commercial and corporate strategy and has significant national and global launch experience. He has helped a diverse set of clients from big pharma to biotech solve a wide range of challenges, including US entry strategy, EU launch excellence, due diligence, and portfolio optimization. Close to 20 years ago, he began his career in the pharmaceutical industry as a sales representative before moving into increasingly senior commercial roles at the local and global level.

Ed earned an MA in biological sciences from Brasenose College, University of Oxford. He is also a Lean Six Sigma Black Belt and is PRINCE2 project management qualified.

Articles by Ed Corbett

Change Is Happening in the EU: What Pharma Companies Need to Know About the European Union’s New Pharmaceutical Strategy

For the first time, the European Union is undergoing a major overhaul of its pharmaceutical industry with the new Pharmaceutical Strategy for Europe, which was launched in late 2020.    Through this strategy, the European Union (EU) is making changes to its infrastructure with the goal of building a holistic, patient-centered, forward-looking pharmaceutical landscape for all EU member […]

When America Sneezes, the World Catches a Cold: How Changes to U.S. Drug Pricing Will Affect the Globe

Through an intense U.S. election season, there is one issue that patrons of the right and left agreed on: The cost of prescription drugs is viewed as unfair and unsustainable. With President Joe Biden in office, his team should take prescription drug pricing policies into careful consideration – because when the U.S. sneezes, the world […]

Achieve Price and Access Launch Excellence in a Disrupted World

With the U.S. election behind us, the soaring costs of U.S. healthcare have become a priority for politicians—in particular, the cost of prescription drugs. Some proposed solutions involve external reference pricing from comparable countries and limiting drug price increases. These anticipated changes in U.S. pricing policy, coupled with the downward pressure on drug budgets due to the COVID-19 pandemic, suggest that pharma companies must think globally when setting launch prices.   In this webinar, Ed Corbett and Alan Crowther discuss key challenges that can impact […]

Unlock Europe To Create Value

The European Union (EU) is the second largest pharma market in the world and represents a major opportunity for U.S. biotechnology companies. Due to the perceived complexity of launching in Europe, many biotech companies licence their products to partner companies. Often as a result, the full value of the product is not realised by the […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.